| Symbol
| ADAM8
| contributors: mct - updated : 12-02-2016
|
| HGNC name
| ADAM metallopeptidase domain 8
|
| HGNC id
| 215
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
|
| gain of function
|
in various tumors including lung and brain tumors  | | tumoral
|
|
| --over
|
| |
of novel truncated forms of ADAM8, associated with increased invasive abilities and osteoclastogenic properties, and correlated with the early development of metastatic lesions | | tumoral
|
|
| --over
|
| |
in breast tumors and derived metastases compared to normal tissue, especially in triple-negative breast cancers (TNBCs) | | tumoral
|
|
| --over
|
| |
associated with poor overall survival in patients with hepatocellular carcinoma | |
Variant & Polymorphism
| 
| |
Candidate gene
| Marker
| prognostic marker for renal cell carcinomas and the best predictor of distant metastasis | Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| allergy | | | |
| potential target for therapeutic intervention in allergy and inflammation
| | cancer | digestive | pancreas | |
| ADAM8 is a target for PDAC therapy | | cancer | reproductive | breast | |
| represents a promising novel target for treatment of TNBCs, which currently lack targeted therapies and frequently progress with fatal dissemination | | cancer | digestive | liver | |
| may be a potential target of antiangiogenic therapy for HCC |
| | |
|
| skeletal muscle of dystrophin-null mice, an animal model for Duchenne Muscular Dystrophy, deteriorates by the lack of Adam8, which is characterized by increased area of muscle degeneration and increased number of necrotic and calcified muscle fibers |